The recent push by the US to cut drug prices could have unintended consequences for European patients, potentially leading to longer waits for new medicines. A study published in The Lancet indicates that as US drugmakers align prices with those in countries like Germany and France, they may delay launches in Europe to avoid financial losses. This could significantly impact patients with serious conditions who rely on timely access to innovative treatments.
The study highlights that three in four of the 195 patented medicines examined could see companies prioritising the US market, the largest pharmaceutical market globally, over European launches. This shift could result in a 35% drop in drug launches in the EU, as seen in recent months, raising concerns about the availability of essential treatments.
European health officials are now facing pressure to reconsider their healthcare budgets to ensure timely access to new medicines. The European Patients Forum warns that delays in drug availability could lead to detrimental health outcomes for patients, particularly those with progressive diseases.
While the US may save billions through this pricing policy, the potential for delayed access in Europe raises questions about the overall effectiveness of the strategy. The European Commission is currently assessing the impact of these US policies on drug availability and pricing within the EU, as the situation continues to evolve.
Source: Euronews
